CritCat (2016-2019) placed TETHIS in a multinational RIA consortium working on rational design of nanoparticle catalysts to replace critical platinum-group materials in fuel cell electrodes.
TETHIS SPA
Italian deep-tech SME engineering nanostructured surfaces for PGM-free fuel cell catalysts and circulating tumor cell diagnostics.
Their core work
TETHIS is a Milan-based materials technology SME specializing in advanced nanostructured surface engineering, applied across two distinct domains: clean energy catalysis and biomedical diagnostics. In energy, they work on designing transition metal nanoparticle catalysts as replacements for expensive platinum-group metals (PGMs) in fuel cells and electrocatalytic applications, combining experimental synthesis with machine learning-assisted materials screening and first-principles simulations. In diagnostics, they develop surface-based platforms for detecting and characterizing circulating tumor cells, suggesting their nanostructured surface expertise is transferable across industries. This dual application of the same core competency — engineering functional surfaces at the nanoscale — is what makes them unusual among Italian deep-tech SMEs.
What they specialise in
CritCat keywords cite 'transition metal nanoparticles' and 'nanoparticle control' as core deliverables, indicating hands-on material fabrication capability.
CritCat involvement included machine learning and first-principles simulations for materials screening, suggesting TETHIS contributes computational as well as experimental expertise.
TETHIS-SBS-CTC (2018), which TETHIS coordinated under SME Instrument Phase 1, targeted an innovative platform for isolating and characterizing circulating tumor cells — a distinct but surface-engineering-adjacent application.
How they've shifted over time
TETHIS entered H2020 through CritCat (2016) squarely in the clean energy materials space — electrocatalysis, fuel cells, and PGM replacement — applying both experimental nanoparticle work and computational tools. By 2018 they were simultaneously pursuing a self-led SME Instrument project in cancer diagnostics, indicating a deliberate pivot to commercializing their surface engineering know-how in the biomedical market. The absence of keywords in the second project and the short SME-1 duration (within-year, 2018–2018) suggest this was an early-stage feasibility study rather than a mature product, so the biomedical thread may still be exploratory rather than established.
TETHIS appears to be moving from foundational energy-materials research participation toward proprietary diagnostic product development, using their nanostructured surface platform as a horizontal technology across sectors.
How they like to work
TETHIS has operated both as a consortium participant (CritCat RIA, alongside likely academic and larger industrial partners) and as a project coordinator (TETHIS-SBS-CTC SME-1, where they drove their own commercial pitch). Their small total partner count (9 unique partners across just 2 projects) suggests they work in focused, compact teams rather than large open consortia. This profile is typical of a technology-product SME that joins research consortia for access to expertise and then leads when commercializing its own IP.
TETHIS has built connections with 9 partners across 5 European countries through two projects, suggesting a functional but limited network concentrated around their two application domains. No evidence of repeated partnerships with the same organizations, so their network is breadth-first rather than relationship-deep.
What sets them apart
TETHIS occupies an unusual position as an SME that applies the same nanostructured surface engineering platform to both clean energy (fuel cell catalysts) and oncology diagnostics (tumor cell capture) — making them one of the few Italian SMEs with genuine cross-sector deep-tech credentials. Their combination of ML-assisted materials design with experimental nanofabrication is rare at SME scale and positions them as a credible bridge between computational materials science and industrial application. For consortium builders, they bring proprietary platform technology rather than generic research capacity, which is more valuable in exploitation-oriented projects.
Highlights from their portfolio
- CritCatLargest funding received (€311,596), tackling the high-priority challenge of replacing scarce platinum-group metals in fuel cells — directly relevant to the EU's critical raw materials agenda and clean hydrogen economy.
- TETHIS-SBS-CTCTETHIS acted as coordinator and sole named entity in this SME Instrument Phase 1 project, meaning this was their own commercial concept — a diagnostic platform for circulating tumor cells — rather than a collaborative research role.